Home > Publications Database > The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. > print |
001 | 276324 | ||
005 | 20250314091251.0 | ||
024 | 7 | _ | |a 10.1111/ene.16562 |2 doi |
024 | 7 | _ | |a pmid:39878395 |2 pmid |
024 | 7 | _ | |a 1351-5101 |2 ISSN |
024 | 7 | _ | |a 1468-1331 |2 ISSN |
024 | 7 | _ | |a altmetric:173681251 |2 altmetric |
037 | _ | _ | |a DZNE-2025-00287 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Alefanti, Ioanna |b 0 |
245 | _ | _ | |a The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. |
260 | _ | _ | |a Oxford [u.a.] |c 2025 |b Wiley-Blackwell |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1738752355_12998 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a The p.A53T variant in the SNCA gene was considered, until recently, to be the only SNCA variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) SNCA pathogenic variant in five affected individuals of three Greek families, leading to autosomal dominant PD. This study aims to further explore the presence and phenotypic expression of this variant in the Greek PD population.Restriction fragment length polymorphism (RFLPs) was used for genotyping of 664 Greek PD cases. Detailed clinical information was obtained for the carriers and p.A30G-positive samples underwent haplotype analysis.We identified 10 additional p.A30G-positive PD patients (1.5%), of whom 4 were sporadic cases (0.9%). They manifested typical Parkinsonian motor dysfunction, with a mean age of onset of 51.7 years (range: 33-62) and a broad spectrum of non-motor symptoms. The absence of affected first degree relatives in four out of ten index cases, and the presence of a phenocopy in an additional family, suggest that the p.A30G variant manifests reduced penetrance. The common haplotype among the p.A30G carriers confirmed a founder effect. Furthermore, two asymptomatic carriers were identified, with possible premotor manifestations.These findings underscore that the p.A30G SNCA pathogenic variant represents an important, albeit rare, cause of genetic PD in the Greek population. This is the first time in which a genetic synucleinopathy, with a variant in the SNCA gene, is clearly linked to an appreciable frequency of sporadic PD in a particular population. |
536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 1 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
650 | _ | 7 | |a SNCA |2 Other |
650 | _ | 7 | |a Greek population |2 Other |
650 | _ | 7 | |a Parkinson's disease |2 Other |
650 | _ | 7 | |a p.A30G |2 Other |
650 | _ | 7 | |a alpha-Synuclein |2 NLM Chemicals |
650 | _ | 7 | |a SNCA protein, human |2 NLM Chemicals |
650 | _ | 2 | |a Humans |2 MeSH |
650 | _ | 2 | |a alpha-Synuclein: genetics |2 MeSH |
650 | _ | 2 | |a Parkinson Disease: genetics |2 MeSH |
650 | _ | 2 | |a Greece |2 MeSH |
650 | _ | 2 | |a Male |2 MeSH |
650 | _ | 2 | |a Middle Aged |2 MeSH |
650 | _ | 2 | |a Female |2 MeSH |
650 | _ | 2 | |a Adult |2 MeSH |
650 | _ | 2 | |a Aged |2 MeSH |
650 | _ | 2 | |a Pedigree |2 MeSH |
650 | _ | 2 | |a Haplotypes |2 MeSH |
650 | _ | 2 | |a Genetic Predisposition to Disease: genetics |2 MeSH |
700 | 1 | _ | |a Koros, Christos |0 0000-0001-5806-0717 |b 1 |
700 | 1 | _ | |a Tsami, Viktoria |b 2 |
700 | 1 | _ | |a Simitsi, Athina Maria |b 3 |
700 | 1 | _ | |a Kartanou, Chrisoula |b 4 |
700 | 1 | _ | |a Papagiannakis, Nikolaos |b 5 |
700 | 1 | _ | |a Bozi, Maria |b 6 |
700 | 1 | _ | |a Antonelou, Roubina |b 7 |
700 | 1 | _ | |a Maniati, Matina |b 8 |
700 | 1 | _ | |a Hauser, Ann-Kathrin |0 P:(DE-2719)2351249 |b 9 |u dzne |
700 | 1 | _ | |a Varvaressos, Stefanos |b 10 |
700 | 1 | _ | |a Bonakis, Anastasios |b 11 |
700 | 1 | _ | |a Lourentzos, Konstantinos |b 12 |
700 | 1 | _ | |a Makrythanasis, Periklis |b 13 |
700 | 1 | _ | |a Papageorgiou, Sokratis G |b 14 |
700 | 1 | _ | |a Proukakis, Christos |b 15 |
700 | 1 | _ | |a Potagas, Constantinos |b 16 |
700 | 1 | _ | |a Gasser, Thomas |0 P:(DE-2719)2320009 |b 17 |u dzne |
700 | 1 | _ | |a Koutsis, Georgios |b 18 |
700 | 1 | _ | |a Karadima, Georgia |b 19 |
700 | 1 | _ | |a Stefanis, Leonidas |b 20 |
773 | _ | _ | |a 10.1111/ene.16562 |g Vol. 32, no. 2, p. e16562 |0 PERI:(DE-600)2020241-6 |n 2 |p e16562 |t European journal of neurology |v 32 |y 2025 |x 1351-5101 |
856 | 4 | _ | |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.docx |
856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287.pdf |
856 | 4 | _ | |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.doc |
856 | 4 | _ | |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.odt |
856 | 4 | _ | |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287%20SUP.pdf |
856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/276324/files/DZNE-2025-00287.pdf?subformat=pdfa |
909 | C | O | |o oai:pub.dzne.de:276324 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2351249 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 17 |6 P:(DE-2719)2320009 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 1 |
914 | 1 | _ | |y 2025 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-12 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NEUROL : 2022 |d 2024-12-12 |
915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2024-12-12 |w ger |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-12 |
915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-12 |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NEUROL : 2022 |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-12 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-12 |
920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 0 |
920 | 1 | _ | |0 I:(DE-2719)1240005 |k ICRU |l Core ICRU |x 1 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a UNRESTRICTED |
980 | _ | _ | |a I:(DE-2719)1210000 |
980 | _ | _ | |a I:(DE-2719)1240005 |
980 | 1 | _ | |a FullTexts |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|